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Abstract
Background: Long non-protein-coding RNAs (lncRNAs) are involved in the pathological processes of nervous
system diseases. NONRATT021972 is an lncRNA. This study explores the effects of lncRNA NONRATT021972 small
interference RNA (siRNA) on diabetic neuropathic pain (DNP) mediated by the P2X7 receptor in the rat dorsal root
ganglia (DRG).
Results: Our results show that NONRATT021972 expression was significantly higher in the DRG of diabetes mellitus
(DM) group compared with control group. NONRATT021972 expression in the DRG was reduced when DM rats
were treated with NONRATT021972 siRNA. NONRATT021972 siRNA treatment in type 2 DM rats increased the
mechanical withdrawal threshold (MWT), the thermal withdrawal latency (TWL) and the sensory nerve conduction
velocity (SNCV) of rat tail nerves. After intravenous injection with NONRATT021972 siRNA in DM rats, the P2X7, GFAP
and TNF-ɑ expression levels in DRG were decreased. An interaction between the RNA (NONRATT021972) and
protein (P2X7) was predicted by the application of bioinformatics technology. The BzATP-activated currents in DRG
non-neurons (satellite glial cells) of DM rats were significantly increased compared to control rats. NONRATT021972
siRNA treatment inhibited the ATP-activated currents in HEK293 cells transfected with pEGFP-P2X7.
Conclusions: NONRATT021972 siRNA treatment can decrease the expression levels of P2X7 mRNA and protein and
inhibit the activation of satellite glial cells (SGCs) in the DRG of type 2 DM rats. Moreover, NONRATT021972 siRNA
treatment reduced the release of inflammatory factors (TNF-α), thereby inhibiting the excitability of DRG neurons
and reducing mechanical and thermal hyperalgesia in type 2 DM rats.
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Background
Long non-protein-coding RNAs (lncRNAs) are classified
as transcripts that are >200 nucleotides (nt) in length [1,
2]. LncRNAs can be transcribed range from 200 bp up
to several kilobases in length from either strand and
sorted as sense, antisense, bidirectional, intronic, or
intergenic based on their nearby protein-coding genes
[1–3]. Transcription and post-transcriptional RNA pro-
cessing, translation, DNA methylation and chromatin
architecture are regulated by lncRNAs through local
(cis) and long distance (trans) mechanisms [2–4].
LncRNAs can produce a complex regulatory network
through interactions with transcription factors, co-
activators and/or repressors to influence different as-
pects of gene transcription [1, 3, 5]. The knockout of
some lncRNAs in mice resulted in abnormal functions
[3–5]. LncRNAs are also involved in the pathological pro-
cesses of nervous system diseases [3, 6].
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Diabetes mellitus (DM) has become a global epidemic,
with an incidence of 11.6 % in our country (representing
113.9 million people). Diabetic neuropathic pain (DNP)
is one of the most common chronic complications of
diabetes and has typical symptoms of nerve pathological
pain, including spontaneous pain, hyperalgesia, and allo-
dynia. Intractable pain induced by diabetes mellitus has
become a substantial problem in the field of pain ther-
apy [7]. Fifty percent of diabetic patients suffer from
DNP [8]. Studies have shown that people with pre-
diabetes are also likely to suffer from neuropathy. Thus,
the number of diabetes patients with nerve pathological
pain is enormous.
Adenosine triphosphate (ATP) and its analogues
bind to P2 receptors [9–11]. P2 receptors can be di-
vided into P2X and P2Y receptors. P2X receptors are
ligand-gated ion channels (P2X1–7) [9, 10]. Dorsal
root ganglia (DRG) transmit sensory signals from the
peripheral nerve to the spinal cord [12]. P2X7 recep-
tor expressed in satellite glial cells (SGCs) is involved
in the pain transmission and the occurrence of neuro-
pathic pain in DM patients [9, 13]. Sensitivities to
mechanical pain and thermal pain were significantly
decreased in P2X7 receptor-knockout mice compared
with wild- type mice [13]. Conversely, P2X7 receptor
expression was increased by inflammatory injury [14].
Furthermore, antagonists of the P2X7 receptor could
inhibit the pain behavior of neuropathic pain rat [15].
NONRATT021972 is an lncRNA (http://www.nonco-
de.org/show_rna.php?id= NONRATT021972) [16]. At
now lncRNA functions are unclear. Our studies showed
that the expression levels of lncRNA NONRATT021972
were augmented in the DRG of type 2 DM rat. There-
fore, lncRNA NONRATT021972 might participate in
the transmission of nociceptive signaling. Inhibiting
lncRNA functions in vivo may have therapeutic potential
for some diseases [3–5]. This project explored the effects
of small interfering RNA (siRNA) treatment against
lncRNA NONRATT021972 on the up-regulated expres-
sion of P2X7 receptor in DRG and the neuropathic pain
behaviors in type 2 DM rats. Our work may provide a
new experimental basis for the prevention and allevi-
ation of diabetic neuropathic pain.
Results
Effects of NONRATT021972 siRNA on NONRATT021972
expression in DRG
Misexpression of lncRNAs was associated with nervous
system diseases. The expression of NONRATT021972 in
DRG was evaluated by real-time PCR. The expression of
NONRATT021972 in DRG from the DM group was sig-
nificantly higher than that in the control group (Fig. 1a).
Treatment of the DM rats with NONRATT021972
siRNA decreased the expression of NONRATT021972
compared to the DM group (Fig. 1a). The expression of
NONRATT021972 in DRG was also evaluated by in situ
hybridization(ISH). The expression of NONRATT021972
in the DM group was significantly higher than that in the
control group (Fig. 1b). The in situ expression of NON-
RATT021972 in DRG was also reduced when the DM rats
were treated with NONRATT021972 siRNA (Fig. 1b).
Our results showed that the expression of NON-
RATT021972 in the DRG was significantly increased in
the DM group than in the control group.
Effects of NONRATT021972 siRNA on mechanical
hyperalgesia and thermal hyperalgesia
Mechanical hyperalgesia and thermal hyperalgesia will
be increased during diabetic neuropathic pain state. The
effects of the NONRATT021972 si treatment on mech-
anical hyperalgesia were tested by using von Frey fila-
ments. No difference in the mechanical withdrawal
threshold (MWT) was observed among the groups at
the 4th week of the experiment (F(3,20) = 1.94, p > 0.05).
At the 6th week of the experiment, the MWT in the
DM, DM +NONRATT021972 si, and DM +NC si rats
was lower than that in the control rats (F(3,20) = 9.48,
p < 0.01). There was no significant difference among
the DM, DM +NONRATT021972 si, and DM +NC si
groups (F(2,15) = 0.2, p > 0.05). One week after injection
with NONRATT021972 si, the MWL in the DM +
NONRATT021972 si group was higher than that in
the DM group (p < 0.05) (Fig. 2a).
The effects of the NONRATT021972 si on thermal
hyperalgesia were measured by Thermal Paw Stimula-
tion System. At the end of the 4th and 6th weeks of
the experiment, the TWL in the DM, DM +NON-
RATT021972 si, and DM +NC si rats was lower than
that in the control rats. There was no significant dif-
ference among the DM, DM +NONRATT021972 si,
and DM +NC si groups (F(2,15) = 0.90, p > 0.05). One
week after injection with NONRATT021972 si, the
MWL in the DM +NONRATT021972 si group was
higher than that in the DM group (p < 0.001) (Fig. 2b).
The data revealed MWT and TWL in type 2 diabetic
model rats were increased after NONRATT021972
siRNA treatment.
Effects of NONRATT021972 siRNA on sensory nerve
conduction velocity
Measurement of sensory nerve conduction velocity is
used to test the function of nerves [17]. At the end
of the 4th and 6th weeks of the experiment, the SNCV
in the DM, DM +NONRATT021972 si, and DM +NC
si rats was lower than that in the control rats (p <
0.05). There was no significant difference among the
DM, DM +NONRATT021972 si, and DM +NC si
groups (p > 0.05). One week after injection with
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NONRATT021972 si, the SNCV in the DM +NON-
RATT021972 si group was higher than that in the
DM group (p < 0.05) (Fig. 3). Thus, the SNCV in the
DM rats treated with NONRATT021972 siRNA was
significantly enhanced compared with the SNCV in
the DM rats.
Effects of NONRATT021972 si on P2X7 mRNA and protein
expression in the DRG
P2X7 receptor is involved in neuropathic pain. The op-
tical density values (ODV) of P2X7 mRNA (Fig. 4a) and
protein (Fig. 4b) expression in the four groups were
standardized to β-actin. The optical density values of the
P2X7 mRNA and protein expression in the DM group
were higher than those in the control group (p < 0.001).
The expression levels of the P2X7 mRNA and protein
in the DM +NONRATT021972 si group were lower
than those in the DM group (p < 0.001). There was
no significant difference between the DM group and
the DM +NC si group (p > 0.05). Therefore, NON-
RATT021972 siRNA treatment can influence the up-
regulation of P2X7 receptor in the DM rats.
Effects of NONRATT021972 siRNA on the coexpression of
P2X7 and GFAP in DRG based on immunofluorescence
GFAP is the marker of satellite glial cells (SGCs). The
up-regulation of GFAP in the DRG suggests the acti-
vation of SGCs after nervous injury stimulus [18].
The coexpression values of the P2X7 receptor and
GFAP in the four groups at the 7th week of the ex-
periment are shown in Fig. 5. P2X7 and GFAP were
colocalized in the SGCs in DRG. The coexpression
values of the P2X7 receptor with GFAP in the DM
group were higher than that in the control group,
whereas the coexpression values in the DM +NON-
RATT021972 si group were lower than that in the
Fig. 1 Effects of NONRATT021972 siRNA on NONRATT021972 expression in DRG. a The expression of NONRATT021972 in DRG by real-time PCR. The
expression of NONRATT021972 in the DM group was significantly higher than that in the control group. Treatment of the DM rats with NONRATT021972
siRNA decreased the expression of NONRATT021972 compared to the DM group. n= 6, ***p< 0.001 vs control group, ###p< 0.001 vs DM group. b The
expression of NONRATT021972 in DRG evaluated by in situ hybridization (ISH). The expression of NONRATT021972 in DM group was significantly higher
than that in the control group, while it was decreased in the DM rats treated with NONRATT021972 siRNA compared with the DM group. The arrows
indicate the positive cells in DRG. Scale bar: 40 μm. n= 6,***p< 0.001 vs control group, ###p< 0.001vs DM group
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DM group. There was no significant difference be-
tween the DM group and the DM +NC si group.
NONRATT021972 siRNA treatment may decrease the
up-regulation of the P2X7 receptor associated with
SGC activation in the DRG.
Effects of NONRATT021972 si on GFAP and TNF-α in DRG
TNF-α as an inflammatory factor released from SGCs is in-
volved in the initiation and maintenance of neuropathic
pain. The expression values of GFAP (Fig. 6a) and TNF-α
(Fig. 6b) in DRG were determined by western blotting. The
Fig. 2 Effects of NONRATT021972 siRNA on the mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL) in DM rats. a At
the 4th week of the experiment, there was no difference in MWT among the groups. At the 6th week of experiment, the MWT in the DM, DM +
NONRATT021972 si, and DM + NC si rats was decreased compared to the control rats. There was no significant difference among the DM, DM +
NONRATT021972 si, and DM + NC si groups. One week after injection with NONRATT021972 si, the MWL in the DM + NONRATT021972 si group
was higher than that in the DM group. n = 6,**p < 0.01 vs control group, #p < 0.05 vs DM group. b At the end of the 4th and 6th weeks of the
experiment, the TWL in the DM, DM + NONRATT021972 si, and DM + NC si rats was lower than that in control rats. There was no significant
difference among the DM, DM + NONRATT021972 si, and DM + NC si groups. One week after injection with NONRATT021972 si, the MWL in the
DM + NONRATT021972 si group was higher than that in the DM group. n = 6,**p < 0.01, ***p < 0.001 vs control group, ###p < 0.001vs DM group
Fig. 3 Effect of NONRATT021972 siRNA on the SNCV of the tail nerve in DM rats. At the end of the 4th and 6th weeks of the experiment, the
SNCV in DM, DM + NONRATT021972 si, and DM + NC si rats was lower than that in the control rats. There was no significant difference among
the DM, DM + NONRATT021972 si, and DM + NC si groups (p > 0.05). One week after injection with NONRATT021972 si, the SNCV in DM +
NONRATT021972 si group was higher than that in the DM group. n = 6,**p < 0.01, ***p < 0.001 vs control group, ###p < 0.001 vs DM group
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ODV of GFAP and TNF-α were standardized to β-actin.
The expression levels of GFAP and TNF-α in the DM
group were higher than that in the control group (p <
0.001). The expression levels of GFAP and TNF-α in the
DM+NONRATT021972 si group were lower than that in
the DM group (p < 0.001). There was no significant differ-
ence between the DM group and the DM+NC si group
(p > 0.05). It is possible that NONRATT021972 siRNA
treatment decreased the up-regulation of TNF-α and GFAP
in DRG and to reduce the pain behaviors in DM rats.
Fig. 4 Effects of NONRATT021972 siRNA on P2X7 mRNA and protein expression levels in the DRG of DM rats. The optical density values of the
P2X7 mRNA (a) and protein (b) expression in the DM group were higher than those in the control group. The expression levels of the P2X7
mRNA and protein in the DM + NONRATT021972 si group were lower than those in the DM group. n = 6,***p < 0.001vs control group, ###p < 0.001
vs DM group
Fig. 5 The co-expression values of P2X7 and GFAP in the DRG based on double-labeled immunofluorescence. The coexpression of the P2X7 receptor
with GFAP in the DM group was higher than the values in the control group, whereas the coexpression values in the DM+NONRATT021972 si group
were lower than that in DM group. The green signal represents GFAP staining with FITC, and the red signal indicates P2X7 staining with TRITC. Merge
represents the P2X7 and GFAP double staining image. Scale bar: 20 μm
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Predicting the interaction between NONRATT021972 RNA
and P2X7 receptor
Interactions occur between RNA and proteins [19].
These interactions can be rapidly predicted by the appli-
cation of bioinformatics technology (CatRAPID) [20].
CatRAPID is an online algorithm that has a predictive
function. The method can be used to identify the targets
of NONRATT021972 RNA and avoid the blindness of
function research. The CatRAPID results revealed a high
score for the interaction between NONRATT021972
and P2X7 receptor (Fig. 7).
BzATP-activated currents in DRG non-neuronal cells
P2X7 activation in DRG related to neuropathic pain.
P2X7 agonist BzATP (100 μM)-activated currents in
DRG non-neuronal cells isolated from control rats and
DM rats were recorded using a whole cell patch clamp.
The results showed that the BzATP-activated current in
Fig. 6 Effects of NONRATT021972 siRNA on GFAP and TNF-α expression in the DRG of DM rats. The expressions of GFAP (a) and TNF-α (b) in DM
group showed a significant increase compared to the control group. The DM + NONRATT021972 si group showed an decrease in the levels of
GFAP and TNF-α compared to the DM group. n = 6,***p < 0.001 vs the control group, ###p < 0.001 vs the DM group
Fig. 7 Prediction of the interaction between NONRATT021972 RNA and the P2X7 receptor. A high score was obtained for the interaction
between NONRATT021972 and the P2X7 receptor. The red color represents the area of the interaction
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the DM group was larger than that in the control group
(p < 0.001) (Fig. 8). Thus, P2X7 activation in DRG
enhanced the pain behaviors in the DM rats.
Effects of NONRATT021972 siRNA on the ATP-activated
current in HEK293 cells
We compared the difference of the ATP-activated
currents between HEK293 cells transfected with pEGFP-
hP2X7 plasmid alone or co-transfected with pEGFP-
hP2X7 plasmid and NONRATT021972 siRNA. The
ATP-activated current in HEK293 cells can be blocked
by A-438079 (a selective antagonist of the P2X7 recep-
tor) (Fig. 9a). The results showed that the ATP-activated
currents in the cells transfected with pEGFP-hP2X7
plasmid alone were larger than those in the cells co-
transfected with pEGFP-hP2X7 plasmid and NON-
RATT021972 siRNA (p < 0.05) (Fig. 9b, c). The results
support that the NONRATT021972 siRNA treatment re-
duced pain behaviors in the DM rats by inhibiting the
P2X7 receptor in DRG.
Discussion
Many in vitro studies confirmed that lncRNAs have im-
portant cellular functions [1, 5]. Experiments using genetic
knockout animal models revealed that multiple lncRNAs
functioned in disease pathogenesis [3, 6, 21, 22]. Recent
studies suggested directions for the development of dis-
ease therapies targeting lncRNAs [3, 6, 21, 22]. Our results
showed that the expression of NONRATT021972 in the
DRG was significantly higher in the DM group than in the
control group based on real-time PCR and ISH. The ex-
periments demonstrated that misexpression of lncRNAs
was associated with numerous diseases, including nervous
system diseases [3, 5, 6]. Our studies also revealed
that the expression of NONRATT021972 in DRG
from DM rats treated with NONRATT021972 siRNA
decreased compared with DM group. Thus, the up-
regulation of NONRATT021972 in DRG may be asso-
ciated with the pathological changes that contribute
to diabetic neuropathic pain.
Chronic pain is a major public health problem [23–25].
DNP has the typical symptoms of neuropathy pain,
including spontaneous pain, hyperalgesia and allodynia
[24, 25]. Strategies targeting some lncRNAs have reported
inhibitory effects against abnormal cells in vitro and in
vivo [26, 27]. The MWT and TWL in type 2 diabetic
model rats were lower than those in the control rats in
this study. Our experimental results showed that the
MWT and TWL in type 2 diabetic rats treated with the
NONRATT021972 siRNA in vivo were increased com-
pared with those in the DM rats. Therefore, suppressing
NONRATT021972 may relieve neuropathic pain behav-
iors of type 2 diabetic rats. However, the mechanism
underlying the effect of the NONRATT021972 siRNA on
the neuropathic pain in type 2 diabetic rats is unknown.
Sensory nerve conduction velocity (SNCV) of the tail
nerve is an index of nerve function [17]. SNCV in type 2
DM rats was significantly lower than the control rats,
suggesting that there were abnormal changes in the
structure and function of the primary sensory afferent
nerves. The abnormal changes in the SNCV in DM
group were likely to be the pathological basis of diabetic
neuropathic pain. Inflammatory injury stimulus in the
pathological condition of type 2 DM can affect the
SNCV of primary sensory afferent nerves [17]. Addition-
ally, P2X7 activation can increase the inflammatory re-
sponses [9, 13]. The SNCV in type 2 diabetic rats
treated with NONRATT021972 siRNA was significantly
increased compared with type 2 diabetic rats. Combined
with the down-regulation of the P2X7 mRNA and protein
expression and GFAP or TNF-α expression in DRG, our
results suggested that NONRATT021972 siRNA treat-
ment might reduce the inflammatory injury in DRG sen-
sory afferent nerves. Consequently, NONRATT021972
siRNA treatment may improve the function of primary
sensory nerves to decrease the mechanical and thermal
hyperalgesia of type 2 DM rats.
DRGs accept the impulse from peripheral nociceptive
stimuli and transmit the signal to the central nervous
system [12, 28]. The P2X7 receptor expressed in DRG is
Fig. 8 BzATP-activated currents recorded by a whole cell patch clamp. a BzATP-activated currents in DRG non-neurons (satellite glial cells) from
control and DM rats. The current traces were recorded by the application of 100 μM BzATP. b The BzATP-activated current in the DM group was
lager than that in the control group. The histogram shows the normalized, mean peak current (mean ± SD, n = 12,***p < 0.001)
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closely associated with pain [9, 13]. We observed that
the P2X7 mRNA and protein expression levels in the
DRG of type 2 DM rats were significantly increased
compared with control rats. After treatment of the DM
rats with NONRATT021972 siRNA, the expression
levels of P2X7 mRNA and protein in DRG were de-
creased compared to DM rats. Thus, NONRATT021972
siRNA treatment could inhibit P2X7 receptor to influ-
ence the pathological process of DNP.
Primary sensory ganglia, particularly in DRG, contain cell
bodies of sensory neurons and satellite glial cells (SGCs)
that closely surround the neurons [18, 29]. SGCs can com-
municate with neurons via signaling molecules [18, 29, 30].
The SGCs in DRG mainly express P2X7 receptor [31]. We
observed that P2X7 receptor was co-expressed with GFAP
in SGCs based on immunohistochemistry. The coexpres-
sion levels of P2X7 and GFAP in DRG were up-regulated in
the DM rats compared with the control rats. Notably,
GFAP is an SGC marker [18], and nervous system patho-
logical injuries can cause SGC activation [32–34]. In the
type 2 DM rats, NONRATT021972 siRNA treatment re-
duced the up-regulated coexpression values of P2X7 and
GFAP in DRG. Therefore, the NONRATT021972 siRNA
treatment may suppress the up-regulation of the P2X7 re-
ceptor associated with SGC activation in DRG.
Purinergic signaling involves the interaction between
neurons and SGCs in the DRG [32–34]. ATP released
from nerve endings can activate the P2X7 receptor on
the SGCs in DRG. P2X7 activation then stimulates SGCs
to release cytokines, such as tumor necrosis factor alpha
(TNF-α). Inflammatory factors including TNF-α released
from SGCs are involved in the initiation and mainten-
ance of neuropathic pain [9–11]. TNF-α can strengthen
the excitability of neurons in DRG and enhance its
sensitivity to nociceptive stimuli [29, 30, 32]. ATP can
activate the P2X7 receptor in DRG to mediate the inter-
action between neurons and SGCs [29, 32, 33]. Our re-
sults showed that the expression levels of GFAP and
TNF-α in the DM group were higher than those in the
control group. After treating the DM rats with NON-
RATT021972 siRNA, the expression levels of GFAP and
TNF-α in the DRG were significantly decreased. Thus,
NONRATT021972 siRNA treatment may block P2X7
activation in the DRG to inhibit the up-regulation of
TNF-α and GFAP and to decrease the pain behaviors of
type 2 diabetic rats.
RNA is known to interact with proteins [19]. The ap-
plication of bioinformatics technology can rapidly pre-
dict RNA-protein interactions [20]. We used the
CatRAPID online algorithm to evaluate the interaction
Fig. 9 Effects of NONRATT021972 siRNA on the ATP-activated current in HEK293 cells transfected with pEGFP-hP2X7 plasmid. NONRATT021972
siRNA reduced the ATP-induced currents in HEK293 cells expressing the hP2X7 receptor. a Whole cell patch clamp recordings were performed on
the HEK293 cells expressing P2X7 alone. The plasmid was tagged with EGFP to enable the detection of the transfected cells. Inward currents were
evoked by 100 μM ATP at a holding potential of −60 mV. The currents can be inhibited by 10 μM A-438079 (a selective antagonist of the P2X7
receptor). b ATP activated currents were recorded in the HEK293 cells transfected with P2X7 alone or cotransfected with NONRATT021972 siRNA.
c The histogram shows the normalized, mean peak current (mean ± SD, n = 12, *p < 0.05)
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tendency of NONRATT021972 and a protein (P2X7 re-
ceptor) based on the secondary structure, hydrogen
bonding and molecular inter-atomic forces. This method
can help to locate targets of an RNA. Our data showed
that the prediction score for the interaction between
NONRATT021972 and the P2X7 receptor was high.
This finding suggests that there is an interaction be-
tween NONRATT021972 and the P2X7 receptor. The
whole cell patch clamp results showed that P2X7 agonist
BzATP-activated currents in DRG non-neurons (satellite
glial cells) from type 2 DM rats were significantly in-
creased compared with control rats. Thus, purinergic
signaling was significantly enhanced in the DRG non-
neurons (satellite glial cells).
The upregulation of purinergic signaling may increase
the release of inflammatory factors from SGCs and pro-
mote the excitability of DRG neurons, which increases
the pain sensitivity in type 2 DM rats. The results from
the HEK293 cell experiment showed that the ATP-
activated current in HEK293 cells co-transfected with
the pEGFP-hP2X7 plasmid and NONRATT021972
siRNA was smaller than that in the cells transfected with
the pEGFP-hP2X7 plasmid alone. The ATP-activated
current in HEK293 cells can be blocked by the P2X7 an-
tagonist A-438079. These results revealed that the
NONRATT021972 siRNA treatment could relieve pain
behaviors in type 2 DM rats by inhibiting the P2X7 re-
ceptor in DRG.
Conclusions
In summary, the P2X7 receptor in DRG plays an import-
ant role in DNP. NONRATT021972 siRNA treatment
can decrease the expression levels of P2X7 mRNA and
protein and the activation of SGCs in the DRG of type 2
DM rats. Furthermore, the NONRATT021972 siRNA
treatment reduced the release of inflammatory factors
(TNF-α), thereby inhibiting the excitability of DRG neu-
rons and reducing the mechanical and thermal hyper-
algesia in type 2 DM rats. These findings highlight the
potential of lncRNA NONRATT021972 as a novel thera-
peutic target in DNP.
Methods
Animal model and groups
Zucker diabetic fatty (ZDF) rats (a type 2 diabetic animal
model) were purchased from Vital River Laboratories
(Beijing, China) at 8 weeks of age and were fed with
Purina 5008 diet [35]. Lean ZDF rats without leptin re-
ceptor mutations [36], were used as the controls. All the
rats were housed in a pathogen-free environment with
continuous access to food and water on a 12-h light–
dark schedule at 21–25 °C. The animals were cared for
following the Medical College of Nanchang University
Committee on the Care and Use of Animals guidelines.
Fasting plasma glucose (FPG) and postprandial blood
glucose (PBG) of the rats were measured. Blood was
collected from the tail vein. An oral glucose tolerance
test was performed by administering an oral glucose load
(2 g/kg glucose by gavage) and by measuring the blood
glucose 2 h after dosing. Diabetes was defined as an FPG
≥7.8 mM or PBG ≥11.1 mM after 6 weeks. Then, the rats
were randomly divided into four groups: control group,
diabetic model group (DM), DM treated with NON-
RATT021972 siRNA group (DM+NONRATT021972 si),
and DM treated with the scrambled siRNA group (DM+
NC si). Each group contained 6 rats. The NON-
RATT021972 siRNA target sequence was TGTGAAT-
CATGGAAATATC. The NONRATT021972 siRNA and
negative control (NC si) were purchased from Invitrogen
(Carlsbad, CA, USA). The EntransterTM-in vivo transfec-
tion reagents were provided by the Engreen Company of
Beijing. 320 μl transfection complex consisting of siRNA
(NONRATT021972 siRNA or NCsi) was injected into the
rats of DM+NONRATT021972 si and DM+NC si
groups through sublingual vein according to the reagent’s
instructions. Control and DM rats were injected with
320 μl saline. The body weight, blood glucose and behav-
ior of the rats were measured at 1, 4, 6 and 7 weeks after
the start of the experiment. After 1 week, the rats were
anesthetized with intraperitoneal administration of 50 mg/
kg sodium pentobarbital, and the DRG were collected.
Behavior study
Measurement of the mechanical withdrawal threshold
(MWT)
Noxious-pressure stimulation was used to evaluate
mechanical hyperalgesia. Unrestrained rats were placed
inside a clear plastic chamber (22 cm × 12 cm × 22 cm)
on a stainless steel mesh floor and allowed to acclimate.
Withdrawal responses to mechanical stimulation were
determined using von Frey filaments (BME-403, Tianjin)
applied through an opening in the stainless-steel mesh
floor of the cage (1 cm × 1 cm grid) to an area adjacent
to the paw. The filaments were applied in the order of
increasing bending force (0.13, 0.20, 0.33, 0.60, 1.30,
3.60, 5.00, 7.30, 9.90, and 20.1 g), with each filament ap-
plied 10 times at intervals of 15 s to different parts of
the midplantar glabrous skin. The strength of the fila-
ments in the series that evoked at least five positive re-
sponses among the ten trials was designated the pain
threshold. Values beyond 20.1 g were recorded as 20.1 g.
Measurement of thermal withdrawal latency (TWL)
Noxious heat stimulation was applied by the Thermal
Paw Stimulation System (BME-410C, Tianjin), and
hyperalgesia was determined using thermal stimulation
by Hargreaves’ test. The rats were placed in a transpar-
ent, square, bottomless acrylic box (22 cm × 12 cm ×
22 cm) on a glass plate. After a 30-min habituation
period, the plantar surface of their paws was exposed to
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a beam of radiant heat. Thermal withdrawal latency
(TWL) was taken as an index of the nociceptive thresh-
old. The light beam was turned off automatically when a
rat lifted its paw, allowing the measurement of time
between the beginning of the light beam and the ele-
vation of the foot. This time was designated as the
paw withdrawal latency. The hind paws were tested
alternately at 5 min intervals. The cut-off time for
heat stimulation was 30 s.
Measurements of sensory nerve conduction velocity
Rats were anesthetized with 10 % chloral hydrate
(300 mg/kg) by intraperitoneal injection. Sensory nerve
conduction velocity (SNCV) was evaluated on the tail
using platinum electrodes adjacent to the nerve to ob-
tain a recording at the end of 1, 4, 6, and 7 weeks after
the experiment. An annular stimulus electrode was lo-
cated in the distal tail nerve. The negative electrode
(black) of the stimulus cathode was located proximal to
the tail nerve, whereas the positive electrode (red) was
located 1 cm distal from the negative electrode. The re-
cording electrode was 10 cm proximal from the stimulus
site. The reference electrode was placed between the
stimulus electrode and the recording electrode. The
stimulus intensity was fixed to 1.2 mA. SNCV was calcu-
lated by the following equation: sensory nerve conduction
velocity (m/s) = the distance between recording electrode
and stimulus electrode (10 cm) × 10/latency (ms).
In situ hybridization (ISH)
The rats were anesthetized. The DRG were dissected im-
mediately and fixed in 4 % paraformaldehyde (PFA) for
2 h at room temperature. Then, they were transferred to
15 % sucrose dissolved in 4 % PFA overnight. Tissues
were sectioned at 15 mm. Diethyl pyrocarbonate (DEPC)
water was used for all of the solutions and appliances of
ISH. After deparaffinization and hydration, the slides
were digested with 20 μg/ml proteinase K (Promega,
Madison) and incubated at 37 °C for 5 min. The slides
were stored for 4 h at 42 °C in the pre-hybridization so-
lution in a humidified chamber and then, covered with
sense or antisense probes (2.6 ng/μl) that were also de-
natured (46 °C for 30 min) and incubated at 46 °C for
18 h. After this period, the slides were washed three
times with stringency wash solution 1 (50 % formamide,
2X SSC) and 2 (2X SSC) at 46 °C for 5 min. The slides
were washed twice in MABT (maleic acid buffer con-
taining Tween 20) for 30 min at 25 °C, transferred to a
humidified chamber and covered with 200 μl of blocking
buffer added to each section (MABT + 2 % BSA, 1 %
blocking reagent (Roche)) for 1 h at 25 °C. Immunode-
tection was performed using anti-DIG alkaline phos-
phatase conjugated to antibody (Roche, Basel) diluted in
blocking solution (1:1000). After incubation for 1 h in a
humidified chamber, the slides were washed five times
with MABT for 10 min at 25 °C each wash. The slides
were washed twice for 10 min with pre-staining buffer
(100 mM Tris pH 9.5, 100 mM NaCl) and incubated in
the dark at 37 °C with NBT/BCIP developing solution
(Roche, Basel). The reaction was stopped by incubating
with PBS (16 h at 4 °C). Finally, the sections were coun-
terstained with Bismarck Brown Y 0.5 % and dehydrated.
The slides were mounted with a cover glass with erv-
mount resin (Easy Path, São Paulo). Hybridization with
sense riboprobes were used as a negative control. The
presence of lncRNA in different tissues of the control
and DM group was semi-quantified according to the
ISH evaluation method proposed by Henke [37].
Quantitative real-time PCR
Total RNA was isolated from the DRG using the TRIzol
Total RNA Reagent (Beijing Tiangen Biotech CO.). The
reverse transcription reaction was completed using a
RevertAid™ First Strand cDNA Synthesis Kit (Fermentas,
Glen Bernie, MD, USA) following the manufacturer’s in-
structions. The primers were designed with the Primer
Express 3.0 software (Applied Biosystems), and the se-
quences were as follows: NONRATT021972, sense 5'-T
AGGATGAGTACCAGTCAGGT-3′; anti-sense 5′-TTT
TTGGTTTTTTGACAGGG-3′, and β-actin, sense 5′-G
CTCTTTTCCAGCCTTCCTT-3′; anti-sense: 5′-CTT
CTGCATCCTGTCAGCAA-3′. P2X7, forward 5′-CTT
CGGCGTGCGTTTTG-3′, reverse 5′-AGGACAGGG
TGGATCCAATG-3′. Quantitative PCR was performed
using SYBR® Green MasterMix in an ABI PRISM® 7500
Sequence Detection System (Applied Biosystems, Inc.,
Foster City, CA, USA). The thermal cycling parameters
were 95 °C for 30 s, followed by 40 cycles of amplifica-
tion at 95 °C for 5 s and 60 °C for 30 s [38]. The amplifi-
cation specificity was determined by the melting curve,
and the results were processed by the software within
the ABI7500 PCR instrument.
Immunohistochemistry
Immunohistochemistry was performed as follows. The
rats’ DRG were removed and placed in 4 % paraformal-
dehyde for 2 h at room temperature. The DRG were
washed in 0.1 M PBS prior to incubation in 20 % sucrose
in PBS overnight. Then, 12-μm-thick sections were cut
using a cryostat (Leica) and mounted onto the slides.
The sections were washed in PBS and incubated in
blocking solution containing 3 % bovine serum albumin
(BSA) in PBS with 0.3 % Triton X-100 for 30 min at
room temperature. Primary antibodies against glial fibril-
lary acidic protein (GFAP) (chicken anti-GFAP, Abcam)
and P2X7 (rabbit anti-P2X7, Abcam) were diluted 1:100
in PBS containing 1 % BSA and incubated overnight at
4 °C. The sections were washed in PBS and incubated
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with the secondary antibody [goat anti-rabbit TRITC
(tetraethyl rhodamine isothiocyanate) (Jackson Immu-
noResearch Inc., West Grove, PA, USA) and goat anti-
chicken FITC (Beijing Zhongshan Biotech CO.)] diluted
1:200 in PBS for 45 min at 37 °C. Finally, the sections
were washed in PBS. Controls omitted the primary anti-
body. The sections were imaged using a fluorescence
microscope (Olympus, Tokyo, Japan). Data were col-
lected from six animals in each group. Five fields ran-
domly selected that contained approximately 50 neurons
each were analyzed from each animal and averaged.
Western blotting
DRG tissues from rats were sampled for western blot ana-
lysis. Total protein was extracted by homogenizing the
DRG sample by mechanical disruption in lysis buffer
(50 mmol/L Tris–Cl, pH 8.0, 150 mmol/L NaCl, 0.1 % so-
dium dodecyl sulfate (SDS), 1 % Nonidet P-40, 0.02 % so-
dium deoxycholate, 100 μg/mL phenylmethylsulfonyl
fluoride, 1 μg/ml aprofinin, and 1 % protease inhibitor)
and incubating on ice for 50 min. The lysates were centri-
fuged at 12,000 × g for 10 min at 4 °C. The supernatants
were collected to measure the protein concentrations
using a bicinchoninic acid assay reagent kit and then
stored at −20 °C for later use. The supernatants were
diluted with sample buffer (250 mmol/L Tris–Cl,
200 mmol/L dithiothreitol, 10 % SDS, 0.5 % bromophenol
blue, and 50 % glycerol) and denatured by heating at 95 °C
for 10 min. Supernatant samples containing 20 μg protein
were loaded onto 10 % SDS-polyacrylamide gels and
transferred to polyvinylidene fluoride membranes. The
polyvinylidene fluoride membranes were blocked for 1 h
at room temperature in 5 % nonfat dried milk in buffer
containing 10 mM Tris–HCl (pH 8.0), 150 mM NaCl, and
0.05 % Tween-20. The membranes were incubated with
the primary antibodies anti-rabbit P2X7 (1:1000, Abcam),
anti-chicken GFAP (1:1000, Abcam), or anti-mouse TNF-
α (1:1000, Affinity) overnight at 4 °C, followed by incuba-
tion with an HRP-conjugated secondary antibody (1:5000,
Beijing Zhongshan Biotech CO.) at room temperature.
The membranes were stripped and incubated with mouse
anti-β-actin (Sigma-Aldrich) to verify equal loading of the
proteins in the western blot analysis. The densities of the
bands were determined using Image J Software.
Rapid prediction of the interaction between RNA and
protein
Bioinformatics technology can be applied to rapidly
predict the interaction between RNA and proteins (fast
predictions of RNA and protein interactions and do-
mains, CatRAPID) [20]. We used the CatRAPID online
algorithm forces to evaluate the interaction of the NON-
RATT021972 RNA and the protein (P2X7 receptor)
based on the secondary structure, hydrogen bonding and
molecular inter-atomic forces. This method can be used
to locate RNA targets.
Isolation of DRG non-neurons
The rats were anesthetized with urethane (1.2 g/kg, in-
traperitoneally, i.p.). The DRG were isolated from the
rats and transferred immediately into Dulbecco’s modi-
fied Eagle’s medium (DMEM, Sigma) at pH 7.4 and
340 mosmol/kg. After removal of the attached nerves
and surrounding connective tissues, the DRGs were
minced with dissecting spring scissors and incubated
with trypsin (0.5 mg/ml; type III, Sigma), collagenase
(1.0 mg/ml; type IA, sigma) and DNase (0.1 mg/ml; type
IV, Sigma) in 5 ml of DMEM at 35 °C in a shaking bath
for 35–40 min. Then, soybean trypsin inhibitor
(1.25 mg/ml; type II-S, Sigma) was added to stop the en-
zymatic digestion. The isolated non-neuronal cells (satel-
lite glial cells) were transferred into a 35-mm culture
dish and kept stationary for 30 min [39]. The experi-
ments were performed at room temperature (20–30 °C).
HEK 293 cell culture and transfection
HEK 293 cells were grown in Dulbecco’s modified
Eagle’s medium supplemented with 10 % fetal bovine
serum and 1 % penicillin and streptomycin at 37 °C in a
humidified atmosphere containing 5 % CO2. The cells
were transiently transfected with the human pcDNA3.0-
EGFP-P2X7 plasmid and NONRATT021972 siRNA
using the Lipofectamine 2000 reagent (Invitrogen) ac-
cording to the manufacturer’s instructions. When the
HEK293 cells were 70–80 % confluent, the cell culture
medium was replaced with OptiMEM two hours prior
to transfection. The transfection media were prepared as
follows: (a) 4 μg of DNA or siRNA diluted into 250 μl
final volume of OptiMEM; (b) 10 μl of Lipofecta-
mine2000 diluted into 250 μl final volume of OptiMEM;
and (c) the Lipofectamine-containing solution was mixed
with the plasmid-containing solution and incubated at
RT for 20 min. Subsequently, 500 μl of the cDNA/Lipo-
fectamine complex solution was added to each well. The
cells were incubated for 6 h at 37 °C in 5 % CO2. After
incubation, the cells were washed in MEM containing
10 % FBS and incubated for 24–48 h. The GFP fluores-
cence was evaluated as a reporter for the transfection
efficiency. Whole-cell patch clamp recordings were per-
formed 1–2 days after transfection [40].
Electrophysiological recordings
Electrophysiological recording was performed using a
patch/whole cell clamp amplifier (Axopatch 200B) [39].
A micropipette was filled with an internal solution (in
mM) containing KCl (140), MgCl2 (2), HEPES (10),
EGTA (11), and ATP (5); the solution’s osmolarity was
adjusted to 340 mosmol/kg with sucrose and its pH was
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adjusted to 7.4 with KOH. The external solution (in
mM) contained NaCl (150), KCl (5), CaCl2 (2.5), MgCl2
(1), HEPES (10), and D-glucose (10); the solution’s
osmolarity was adjusted to 340 mosmol/kg with sucrose,
and its pH was adjusted to 7.4 with NaOH. The re-
sistance of the recording electrodes was in the range
of 1 to 4 MΩ, with 3 MΩ being optimal. A small
patch of membrane underneath the tip of the pipette
was aspirated to form a seal (1–10 GΩ), and then
more negative pressure was applied to rupture it to
establish a whole-cell mode. The holding potential
(HP) was set to −60 mV. A-438079 (a selective antag-
onist of P2X7 receptor, Tocris Bioscience, Ellis-ville,
MO), BzATP, and ATP (Sigma Company) were dis-
solved in the external solution and delivered by grav-
ity flow from an array of tubules (500 μm O.D.,
200 μm I.D.) connected to a series of independent
reservoirs. The distance from the tubule mouth to the
examined cell was approximately 100 μm. Rapid solu-
tion exchange was achieved by shifting the tubules
horizontally with a micromanipulator.
Statistical analysis
Significant differences were evaluated using one-way
ANOVA followed by Dunnett’s or Tukey’s tests. The
statistical analyses were performed using GraphPad
Prism version 5.0. The results were expressed as the
mean ± SD. to show variation between groups. Differ-
ences were considered significant when p 0 .05.
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